PPARβ/δ activation might help prevent the development of metabolic disorders, including obesity, dyslipidaemia, type 2 diabetes mellitus and non-alcoholic fatty liver disease. Here, PPARD is linked to obesity due to melanocortin 4 receptor deficiency.